Dror Bashan
President, CEO & Director
Claimed by owner Protalix BioTherapeutics
Former names:
Plant-based Proteins with Improved Therapeutic Profiles
Public on AMEX Dec, 2006
Public on TASE Nov, 2010
Public on TASE Nov, 2010
Protalix BioTherapeutics
www.biospace.com
•
May 10, 2023
FDA Approves Fabry Disease Treatment from Chiesi, Protalix | BioSpace
www.prnewswire.com
•
Dec 21, 2022
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
www.prnewswire.com
•
Dec 5, 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
www.prnewswire.com
•
Sep 12, 2022
Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference
www.prnewswire.com
•
Aug 15, 2022
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results
www.prnewswire.com
•
Apr 4, 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
www.prnewswire.com
•
Mar 31, 2022
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
www.prnewswire.com
•
Nov 15, 2021
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
www.prnewswire.com
•
Jun 2, 2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
www.prnewswire.com
•
Apr 28, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
www.prnewswire.com
•
Apr 28, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
www.prnewswire.com
•
Feb 23, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
www.prnewswire.com
•
Feb 18, 2021
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
www.prnewswire.com
•
Feb 11, 2021
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
www.prnewswire.com
•
Feb 11, 2021
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
www.prnewswire.com
•
Dec 30, 2020
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
fabrydiseasenews.com
•
Dec 22, 2020
FDA Extends Review Date to April for US Approval of PRX-102
www.prnewswire.com
•
Nov 27, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
www.globenewswire.com
•
Oct 2, 2020
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
www.prnewswire.com
•
Sep 8, 2020
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
www.prnewswire.com
•
Aug 11, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
www.prnewswire.com
•
Jun 8, 2020
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
www.prnewswire.com
•
May 28, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
www.finsmes.com
•
Mar 12, 2020
Protalix BioTherapeutics Raises $43.7M in Financing - FinSMEs
www.prnewswire.com
•
Feb 6, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
www.prnewswire.com
•
Dec 19, 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
www.prnewswire.com
•
Dec 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
en.globes.co.il
•
Oct 18, 2019
Protalix up 74% after positive Fabry disease trial results
www.prnewswire.com
•
Sep 24, 2019
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease
www.globenewswire.com
•
Aug 22, 2019
Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships
www.globenewswire.com
•
Aug 13, 2019
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
www.globenewswire.com
•
Jul 29, 2019
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
www.globenewswire.com
•
Jul 17, 2019
Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
www.globenewswire.com
•
Jun 6, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
www.globenewswire.com
•
May 21, 2019
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
globenewswire.com
•
Oct 18, 2017
Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
nocamels.com
•
Oct 14, 2015
Pfizer Invests $10M In Protalix, Pays $36M For Commercial Rights
www.fiercebiotech.com
•
Oct 13, 2015
Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash
About
Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant-cell-based protein expression system. The company's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets.
Protalix gained FDA approval for a plant-cell culture-expressed protein. Elelyso (taliglucerase alfa for injection) is the company's first drug product produced by ProCellEx. Elelyso was approved for marketing by the FDA in May 2012, soon followed by approval from multiple regulatory agencies including the EMA, Australian TGA, Brazilian ANVISA, and the Israeli Ministry of Health. The product has been licensed to Pfizer.
The Protalix ProCellEx platform has the ability to manufacture complex proteins, antibodies, and vaccines and to orally deliver certain therapeutic proteins as demonstrated in animal models.
Protalix gained FDA approval for a plant-cell culture-expressed protein. Elelyso (taliglucerase alfa for injection) is the company's first drug product produced by ProCellEx. Elelyso was approved for marketing by the FDA in May 2012, soon followed by approval from multiple regulatory agencies including the EMA, Australian TGA, Brazilian ANVISA, and the Israeli Ministry of Health. The product has been licensed to Pfizer.
The Protalix ProCellEx platform has the ability to manufacture complex proteins, antibodies, and vaccines and to orally deliver certain therapeutic proteins as demonstrated in animal models.
Primary Sector
Life Sciences & HealthTech
Products
ELELYSO, OPRX-106, PRX-119, PRX-110, UPLYSO, PRX-102, PRX-115, ProCellEx
Geographic markets
Mexico, Uruguay, Chile, Canada, Australia, United States, Brazil
News
(38)
www.biospace.com
•
May 10, 2023
FDA Approves Fabry Disease Treatment from Chiesi, Protalix | BioSpace
www.prnewswire.com
•
Dec 21, 2022
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
www.prnewswire.com
•
Dec 5, 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
www.prnewswire.com
•
Sep 12, 2022
Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference
www.prnewswire.com
•
Aug 15, 2022
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results
www.prnewswire.com
•
Apr 4, 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
www.prnewswire.com
•
Mar 31, 2022
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
www.prnewswire.com
•
Nov 15, 2021
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
www.prnewswire.com
•
Jun 2, 2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
www.prnewswire.com
•
Apr 28, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
www.prnewswire.com
•
Apr 28, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
www.prnewswire.com
•
Feb 23, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
www.prnewswire.com
•
Feb 18, 2021
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
www.prnewswire.com
•
Feb 11, 2021
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
www.prnewswire.com
•
Feb 11, 2021
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
www.prnewswire.com
•
Dec 30, 2020
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
fabrydiseasenews.com
•
Dec 22, 2020
FDA Extends Review Date to April for US Approval of PRX-102
www.prnewswire.com
•
Nov 27, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
www.globenewswire.com
•
Oct 2, 2020
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
www.prnewswire.com
•
Sep 8, 2020
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
www.prnewswire.com
•
Aug 11, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
www.prnewswire.com
•
Jun 8, 2020
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
www.prnewswire.com
•
May 28, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
www.finsmes.com
•
Mar 12, 2020
Protalix BioTherapeutics Raises $43.7M in Financing - FinSMEs
www.prnewswire.com
•
Feb 6, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
www.prnewswire.com
•
Dec 19, 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
www.prnewswire.com
•
Dec 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
en.globes.co.il
•
Oct 18, 2019
Protalix up 74% after positive Fabry disease trial results
www.prnewswire.com
•
Sep 24, 2019
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease
www.globenewswire.com
•
Aug 22, 2019
Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships
www.globenewswire.com
•
Aug 13, 2019
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
www.globenewswire.com
•
Jul 29, 2019
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
www.globenewswire.com
•
Jul 17, 2019
Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
www.globenewswire.com
•
Jun 6, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
www.globenewswire.com
•
May 21, 2019
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
globenewswire.com
•
Oct 18, 2017
Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
nocamels.com
•
Oct 14, 2015
Pfizer Invests $10M In Protalix, Pays $36M For Commercial Rights
www.fiercebiotech.com
•
Oct 13, 2015
Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash
The Team
(7)
DB
ER
Eyal Rubin
SVP & CFO
YN
Yaron Naos
SVP Operations
WT
William Taylor
VP Business Development
RR
Ronen Rosenberg
VP Commercial and Product Planning
DS
Dafna Shelly
VP HR
MK
Michal Kahana
VP QA
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
Undisclosed
Dec 2006
Stock Exchange
AMEX
Valuation
Undisclosed
Undisclosed
Public Offering
Undisclosed
Nov 2010
Stock Exchange
TASE
Valuation
Undisclosed
Undisclosed
Private Equity Funding
B Round
$3.5M
Oct 2004
$3.5M
C Round
$5.3M
Dec 2005
1 Investors
$5.3M
Post-IPO Equity Funding
$10M
Oct 2015
1 Investors
$10M
Post-IPO Equity Funding
$43.7M
Mar 2020
$43.7M
Post-IPO Equity Funding
$40M
Feb 2021
$40M
Media gallery
(1)
Protalix
Locations
Israel
Snunit St 2, Karmiel, Israel
Locations
Israel
Snunit St 2, Karmiel, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,